Third Circuit Rules Drug Manufacturer 340B Contract Pharmacy Restrictions Are Legal
The U.S. Court of Appeals for the Third Circuit unanimously ruled that manufacturer restrictions on 340B contract pharmacy access are lawful and HRSA’s policy prohibiting them is unlawful. 18 manufacturers now restrict contract pharmacy access. Devastating for FQHCs without in-house pharmacies who rely on contract pharmacy arrangements for 340B savings. Combined with the rebate pilot court-ordered pause and expanded audit requirements, 340B contract pharmacy revenue faces pressure from three directions.
Primary source
Bass Berry & SimsFQHC Talent. (2026, January 30). Third Circuit Rules Drug Manufacturer 340B Contract Pharmacy Restrictions Are Legal. Primary source: Bass Berry & Sims. Retrieved April 28, 2026, from https://www.fqhctalent.com/intel/third-circuit-340b-contract-pharmacy-restrictions-legal
More in Risk & Compliance
Jul 5
Section 1557 Language Access Annual Notice Year 1 Anniversary — July 5, 2026 Compliance Window
May 11
URGENT: HHS Section 504 WCAG 2.1 AA Digital Accessibility Deadline Hits FQHCs May 11, 2026 — 3 Weeks Away
Apr 27
HRSA 340B Rebate Model ICR Burden Comment Window Closes April 27 — Second Window for FQHCs After April 20 Main Deadline
Apr 22
Section 504 / WCAG 2.1AA 'Red Alert' — Enforcement Interpretation May Be Contested in Final Weeks Before May 11